Active Ingredient History

  • Now
Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. Esmolol predominantly blocks the beta-1 receptors in cardiac tissue. Used for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.   NCATS

  • SMILES: COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
  • Mol. Mass: 295.38
  • ALogP: 1.53
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$3.2000 - $149.9170
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-[4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester | asl 8052 | asl-8052 | brevibloc | esmolol | (±)-esmolol | esmolol hcl | esmolol hydrochloride | methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate | (±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate | methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue